IC

Ikarian Capital Portfolio holdings

AUM $302M
This Quarter Return
+14.89%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
AUM
$283M
AUM Growth
+$283M
Cap. Flow
+$47.2M
Cap. Flow %
16.65%
Top 10 Hldgs %
54.99%
Holding
128
New
25
Increased
11
Reduced
19
Closed
34
Name Market Value Portfolio Weight Shares or Principal Shares
Change %
Capital Flow
TECX
76
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
$127K 0.02%
+11,179
New +$127K
FHTX icon
77
Foghorn Therapeutics
FHTX
$298M
$106K 0.02%
+15,000
New +$106K
FNCH
78
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$67.5K 0.01%
7,917
-1
-0% -$9
ASLN
79
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$29.8K ﹤0.01%
20,511
MDGL icon
80
Madrigal Pharmaceuticals
MDGL
$9.7B
$17.3K ﹤0.01%
75
PHXM
81
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.26K ﹤0.01%
302
-24,541
-99% -$183K
REPL icon
82
Replimune Group
REPL
$460M
0
SAGE
83
DELISTED
Sage Therapeutics
SAGE
-17,805
Closed -$747K
SRPT icon
84
Sarepta Therapeutics
SRPT
$1.98B
-8,324
Closed -$1.15M
ACAD icon
85
Acadia Pharmaceuticals
ACAD
$4.34B
-60,000
Closed -$1.13M
ACHV icon
86
Achieve Life Sciences
ACHV
$146M
-174,714
Closed -$990K
AKRO icon
87
Akero Therapeutics
AKRO
$3.65B
-50,000
Closed -$1.91M
ALT icon
88
Altimmune
ALT
$325M
-677,300
Closed -$2.86M
AMLX icon
89
Amylyx Pharmaceuticals
AMLX
$877M
-10,000
Closed -$293K
ARGX icon
90
argenx
ARGX
$44.2B
0
ARKG icon
91
ARK Genomic Revolution ETF
ARKG
$1.05B
-46,462
Closed -$1.4M
ARKK icon
92
ARK Innovation ETF
ARKK
$7.43B
-4,519
Closed -$182K
JBIO
93
Jade Biosciences, Inc. Common Stock
JBIO
$245M
-5,576
Closed -$3.94M
AXSM icon
94
Axsome Therapeutics
AXSM
$6.09B
0
AZN icon
95
AstraZeneca
AZN
$255B
0
BIIB icon
96
Biogen
BIIB
$20.8B
-962
Closed -$267K
BMRN icon
97
BioMarin Pharmaceuticals
BMRN
$11.3B
-50,000
Closed -$4.86M
BTAI icon
98
BioXcel Therapeutics
BTAI
$52.7M
-8,313
Closed -$2.48M
CLDX icon
99
Celldex Therapeutics
CLDX
$1.57B
-106,057
Closed -$3.82M
CRSP icon
100
CRISPR Therapeutics
CRSP
$4.82B
0